Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
用户cLCxSEj5otc4
11天前
48
10
已关闭
DOI:
文献链接:
其他信息:

